Lupin

Thus far in the month of February 2026, Laurus Labs surged 13%, while Sun Pharmaceutical Industries and Torrent Pharmaceuticals soared 11% each.

Stocks to Watch today, February 26, 2026: IRFC, RVNL, Sanofi India are among shares that will be eyed by investors today

Lupin management remains confident that the India formulations business will continue to outperform IPM by 1.2-1.3 times, supported by strong sales force and pipeline of new product launches.

Stocks to Watch today, February 25, 2026: Schaeffler India, Aditya Infotech, RVL are among few stocks that will be in focus

Kunal Shah of Mirae Asset ShareKhan expects breakout on the Nifty Pharma index above 23,500 levels; the analyst recommends Lupin, Biocon and Torrent Pharma as top sectoral stock bets.

Axis Securities has named Lupin, Aurobindo Pharma, Max, and Fortis as top picks, citing strong fundamentals, resilient growth drivers, and robust operational execution

Stocks to watch on February 17, 2026: Stocks like Cochin Shipyard, JSW Infrastructure, Lupin, TVS Supply Chain, and Seamec will remain in focus today

Stocks to buy today: Shrikant Chouhan of Kotak Securities suggests placing bets on ICICI Bank and Lupin; here's why

In the December quarter, the company reported a 37 per cent growth in consolidated net profit at ₹1,175.5 crore, as compared to ₹855.16 crore a year ago

The settlement resolves Lupin's ‌pending litigation with Astellas and ​enables the company to continue marketing Mirabegron in the United States

Drug maker Lupin on Wednesday said its subsidiary, Lupin Atlantis Holdings SA (LAHSA), has inked a licence and supply agreement with Galenicum Health for diabetes and weight management medication. Lupin Atlantis Holdings SA (LAHSA) has entered into a partnership with Galenicum for finished formulations of injectable Semaglutide, a GLP-1 receptor agonist. As per the agreement, Galenicum will oversee development, manufacturing, and supply, while Lupin will handle regulatory submissions, approvals, and the commercialisation and distribution of Semaglutide across 23 countries globally, including Canada, Europe, Southeast Asia, and Latin America, the Mumbai-based drug maker said in a statement. "Our partnership with Galenicum marks a strategic milestone in strengthening Lupin's Semaglutide portfolio. As diabetes continues to escalate globally and obesity emerges as a major global health priority, Semaglutide stands out as a critical therapy," said Fabrice Egros, President, Corporate ...

In the past two trading days, the Nifty Pharma index has rallied 3.3 per cent, as compared to 0.41 per cent decline in the Nifty 50.

Lupin has signed an exclusive licensing, supply and distribution deal with China's Gan & Lee for Bofanglutide, a fortnightly GLP-1 injectable for diabetes and weight management in India

Complex generics and better mix fuel recovery cycle

The product, a biosimilar to Amgen's popular drug Neulasta, will be manufactured at Lupin's biotech facility in Pune

Analysts noted that while US generics face margin headwinds, domestic formulations and CDMOs remain resilient. Biosimilars are also poised for growth through new launches and regulatory support.

Drug maker Lupin on Friday said it has launched a generic medication to treat schizophrenia in the US with 180 days of exclusivity. The company has launched Risperidone for extended-release injectable suspension, 25 mg per vial, 37.5 mg per vial, and 50 mg per vial, single-dose vials, with 180-day CGT exclusivity in the US, the Mumbai-based drug maker said in a statement. This follows the recent approval received from the US Food and Drug Administration (USFDA). This is the company's first product using proprietary technology from PrecisionSphere, the Long-acting Injectable (LAI) platform developed by its subsidiary Nanomi BV. Risperidone for extended-release injectable suspension is bioequivalent and therapeutically equivalent to the reference listed drug Risperdal Consta LAI. It is indicated for the treatment of schizophrenia in adults and as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar disorder in adults. As per IQVIA MA

At 1:15 PM, Lupin share price was trading 1.90 per cent higher at ₹2,013.20 per share. In comparison, BSE Sensex was trading 0.91 per cent higher at 84,632.82 levels.

However, on the bourses, Lupin shares were trading 0.70 per cent lower at ₹1,973.50 per share at 9:30 AM. In comparison, BSE Sensex was trading 0.23 per cent lower at 83,346.45 levels.

Stocks to Watch today, November 7, 2025: From Bharti Airtel, LIC, Bajaj Housing Finance, Lupin, here is a list of stocks that will be in focus today